Tulsa Dental Products LLC
$2.7M 122 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Nanovis LLC
Nanovis LLC reported $2,699,986.87 across General Payments, Research, and Ownership to 24 physicians and teaching hospitals across 37 transactions.
- $2.7M Top quartile payer
- All-tracks total
- 37 Below-median volume
- Transactions
- 24 Below-median reach
- Recipients
- +$35.1K
- General Payments vs PY2023
Nanovis LLC reported $2,699,986.87 across all CMS Open Payments tracks (General + Research + Ownership) to 24 physicians and teaching hospitals in Program Year 2024 - ranking #388 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $47,018.78, averaging $112.5K per recipient.
How Nanovis LLC's $2.7M all-tracks total breaks down
Nanovis LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
23/100
Total payments
F
35/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer nanovis-llc Nanovis LLC
$2.7M · #388/1,925 · 0.0% industry · PY2024
- TOT $2.7M
- RANK #388
- SHARE 0.0%
- TXN 37
- RCP 24
- CAT 3
- GEN $47.0K
- ΔGEN +$35.1K
- TOP1 84.8%
- PY 2024
Volume peers
Nearest volume peer: Tulsa Dental Products LLC ($2.7M)
Nanovis LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Nanovis LLC's CMS-reported General Payments increased by $35.1K (+294.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: NANOVIS LLCPY2023: NANOVIS LLCPY2024: Nanovis LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $11,911.69
- PY2024
- $47,018.78
What the Data Shows for Nanovis LLC
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Nanovis LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 3 general-payment categories charted below, "Royalty or License" is the largest at $39.9K across 1 transactions, 84.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 3 types of general payments, Nanovis LLC's largest category was "Royalty or License" at $39.9K - 84.8% of General Payments.
How Nanovis LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $39.9K | 1 | 84.8% |
| Consulting Fee | $5.8K | 5 | 12.4% |
| Food and Beverage | $1.3K | 18 | 2.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $46,467.26 (98.8%) of $47,018.78 in this company's General Payments records across 12 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Nanovis LLC
The five named recipients with the highest reported General Payments from this company
- 1
Richard Rodgers
$39,887.78 across 1 reported transactions
- 2
Thomas J Webster
$5,812.50 across 5 reported transactions
- 3
Douglas Pahl
$321.27 across 4 reported transactions
- 4
Todd Bonvallet
$295.91 across 2 reported transactions
- 5
Asif Shafiq
$149.80 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Nanovis LLC's spend rank (#388 of 1,925, top 20% by spend) and concentration rank (#213 of 1,838, top 12% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Siesta Medical, Inc. : $19.1K total payments, HHI 7498
- Innovative Medical Products, Inc. : $22.8K total payments, HHI 7434
- Teleflex Medical Incorporated : $268.8K total payments, HHI 7395
- Aesculap Biologics, LLC : $5.2K total payments, HHI 7394
- Sequence LifeScience, Inc : $194.5K total payments, HHI 7391
- Elekta, Inc. : $3.2M total payments, HHI 7371
- Nanovis LLC (this company) : $47.0K total payments, HHI 7351
- Atrility Medical, Inc. : $712.50 total payments, HHI 7341
- Dimension Inx Corp : $1.2K total payments, HHI 7329
- Maillefer Instruments Holding Sarl : $369.3K total payments, HHI 7308
- Gentuity, LLC : $144.4K total payments, HHI 7294
- Ortho2, LLC : $37.7K total payments, HHI 7276
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Nanovis LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Nanovis LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Nanovis LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
CVRx, Inc.
$2.7M 16,025 recipients
Compare payment profiles
Galvanize Therapeutics, Inc
$2.7M 830 recipients
Compare payment profiles
Calyxo, Inc.
$2.7M 1,299 recipients
Compare payment profiles
Vertical Orthopaedics, Inc.
$2.7M 19 recipients
Compare payment profiles
OrthoPediatrics Corp.
$2.7M 849 recipients
Compare payment profiles
Put this to use
Nanovis LLC ranks #388 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where Nanovis LLC sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Nanovis LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.